Journal of Research in Medical and Dental Science
2022, Volume 10, Issue S1, Page No: 139-143
Copyright CC BY-NC 4.0
Available Online at: www.jrmds.in
eISSN No.2347-2367: pISSN No.2347-2545

Paracetamol: It's Administration and Associated Effects

Singh VK[1*], Manu Modi[2], Manisha Rastogi[3], Ajay Bilandi[4], Nitin Kumar[5]

[1] *Department of General Medicine, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India*

[2] *Department of Pharmacy, Sanskriti University, Mathura, Uttar Pradesh, India*

[3] *School of Biomedical Engineering, Shobhit Institute of Engineering & Technology, Meerut, Uttar Pradesh, India*

[4] *Department of Pharmaceutical Sciences, RIMT University, Mandi Gobindgarh, Punjab, India*

[5]*Department of Pharmaceutical Chemistry, SGT University, Gurugram, Haryana, India*

ABSTRACT

Paracetamol also known as acetaminophen, it is the most widely used opioid in children for the relief of mild to severe pain. It is used as an analgesic as well as anti-pyretic. In this study, different formulations for administration, its mechanism of action, its pharmaco-kinetics and its long term effects like respiratory disease, gastrointestinal disease, cardiovascular disease, hepatotoxicity, asthma and so on, have been reviewed and analyzed based on the prior literature available, if the drug causes any effect on them or not. Since, mechanism of action of paracetamol is unclear, it is thought to include inhibition of cyclooxygenase 2 (COX2) and is available for over-the-counter preparation. Although the chronic effects are being observed but the occurrence of these adverse effects are quite uncommon. Future perspectives of this drug can be in the direction to further increase the efficiency of the drug and at the same time causing minimal long term effects.

Keywords: Analgesic, Antipyretic, Cyclooxygenase (COX), Dafalgan, Prostaglandin (PG)

HOW TO CITE THIS ARTICLE: Singh VK., Rinka Juneja, Subrata Das, Ajay Bilandi, Nitin Kumar, Paracetamol: It's Administration and Associated Effects, J Res Med Dent Sci, 2022, 10(S1): 139-142. Paracetamol: It's Administration and Associated Effects, J Res Med Dent Sci, 2022, 10(S1): 139-143

Corresponding author: Singh V.K
e-mail ✉ :drvksingh.tmu@gmail.com
Received: 02/05/2022, Manuscript No. JRMDS-22-58444;
Editor assigned: 04/05/2022, PreQC No. JRMDS-22-58444(PQ);
Reviewed: 16/05/2022, QC No. JRMDS-22-58444;
Revised: 19/05/2022, Manuscript No. JRMDS-22-58444(R);
Accepted: 21/05/2022, Published: 15/06/2022

INTRODUCTION

For the first time paracetamol or acetaminophen were synthesized from the *phenacetin* (*precursor*) in the year 1878. Initially, it was not used widely. Since, earlier reports suggested that it was connected to *methaemoglobinaemia* (a condition in which the iron of hemoglobin is converted into ferric state, making it incapable to bind with oxygen). In 1950, these reports were discredited and then it was commercially synthesized in 1950s, being a safe alternative to a potentially carcinogenic and nephrotoxic phenacetin[1]. Aspirin was bypassed by paracetamol for being regarded as one of most commonly used analgesic in UK. This has recently become generally utilized analgesic globally and is recommended by World Health Organization (WHO) as the first analgesic to cure pain caused by cancer.

It is commercialized as an antipyretic and analgesic, but is not prescribed to be used for not more than three days, if not consulted with a doctor. It is also prescribed as a treatment for chronic conditions like lower back pain and osteoarthritis. It is suggested to be a first-line cure in the guidelines of UK. But there are many attempts undertaken by different specialist's societies to remove/eradicate paracetamol from UK's National Institute for Health and Care Excellence (NICE) guidance for the treatment of osteoarthritis, but doing this would left opioids to be one of the main substitue to paracetamol and its dependence will increase[2]. Due to the pandemic of opioid addiction in several states of US, there is a desire that it should not be repeated in UK. Therefore, to introduce opioids in a pain management pathway is not favorable.

DISCUSSION

Studies have suggested that paracetamol usually have decreased analgesic effect as it was thought earlier and therefore, there is a need to define the long- term role of paracetamol at a particular dose. It enables clinicians to have a balance in between the harm and the benefits drug have on an individual person and thereby, regulators can

make recommendation regarding the availability on paracetamol for OTC preparations (Figure 1). Overdosing on paracetamol has well-known acute side effects. The long-period therapeutic implications are less clear. Concerns were expressed regarding paracetamol's effects on cardiovascular, pulmonary, gastrointestinal, central nervous systems and renal, and also on the children of expectant girls who received it.

The analgesic efficacy of paracetamol has also been questioned in the therapy of *osteoarthritis* (OA), a chronic painful disease [3]. To establish evidence-based pharmacologic prescription choices, doctors and patients need current data of benefits as well as risks, and there's been no recent assessment of the genuine hazards associated with paracetamol at standard analgesic dosage.



Figure 1: Structure of Paracetamol. Source [4].

Action Route

Although, precise method for function of the paracetamol is unknown, it is believed to include suppression of cyclooxygenase 2. (COX2). NSAIDs prevents cyclooxygenase (COX) enzymes, inhibiting the *arachidonic* acid from becoming converted to the prostaglandin (PG) G2. Cox enzymes posses a role in the synthesis of prostaglandins, which cause inflammation or discomfort. Because they include their own peroxidase, they convert PGG2 to PGH2, which is subsequently processed by COX enzymes in a variety of adjacent tissues, depending on the individual's needs [5]. In contrast to closely similar nonsteroidal anti-inflammatory drugs (NSAIDs), paracetamol suppresses the peroxidase activity of COX *isozymes*, particularly COX2, whenever the environment of cell is deficient in peroxides and *arachidonic* acid. This answers why the drug paracetamol seemed to have a "key" effect in prior studies (since COX2 is simultaneously present in the neural tissue) or the reason why seems to be ineffective for the damaged tissue (wheat), as seen in rheumatoid arthritis.

Alternatively, the activation of *anandamide reuptake* (and consequent activation of the cannabinoid receptor CB1)) through the metabolite of paracetamol *narachidonoylphenolamine* (AM404), that is formed when deacetylated paracetamol and *arachidonic* acid are combined..

It is general produced due to conjugate formation via sulphate and glucuronide and is excreted subsequently via urine. Cytochrome P450 (CYP) metabolizes roughly 10% of intake paracetamol in order to form *n-acetylpbenzoquinoneimine* (NAPQI) in therapeutic doses, which is then combined with glutathione intracellular and excreted as *mercapturic* acid and cysteine conjugates. And approximately lesser than 5% excretes unchanged.

The formulations for intravenous administration of paracetamol

The large quantity of prescription and non-prescription forms existing attest to paracetamol's pharmacological value[6].Although delivery of paracetamol via oral route is popular in hospitals, its therapeutic use is restricted to the subgroups like highly anaesthetized, sedated, postoperative patients as well as chronically ill patients.

In this case, the delivery via rectal is also used; but, rectal suppositories is believed to have an unstable bioavailability of about 24-98 percent, which is close to the oral formulation bioavailability which is of 63-98.

Differences in the locating as well as the therapeutic efficacy of paracetamol suppositories also led the American Academy of Paediatrics to suggest alternate administration methods. Lastly, the administration through rectal route can be a painful, an uncomfortable, and invasive approach. Therefore, due to the drawbacks mentioned, the advent of IV drugs, each of them having bioavailability of 100%, has been a significant improvement in the therapeutic application of paracetamol.

Synthesis of paracetamol in order to administer it intravenously

Scientists launched the first true form of IV paracetamol under the brand name Perfalgan in 2002. The problem of consistency in the propacetamol formulation had to be resolved in order to produce a stable formulation of paracetamol IV. Paracetamol is turned into 4-aminophenol throughout degradation and swiftly turned into the hepatotoxic substance N-acetyl-p-*benzoquinoneimine* (NAPQI). Paracetamol should be manufactured at the ideal 5-6 pH concentration in order to avoid an enzymatic hydrolysis and therefore the transformation to 4-aminophenol. From the other side, component oxidation processes must be prevented. This is achieved by bubbling nitrogen through IV fluids to reduce the oxygen supply and by utilising hermetically screening oxygen-impermeable glassware vials, which are loaded with such a prepared for using solutions which does not need a further ampoule.

Synthesis of IV Propacetamol for administration

In the raw form, paracetamol has been shown to have a negligible solubility in the water and it is especially susceptible towards light and oxygen in aqueous mediums. Due to this, the active ingredient propacetamol hydrochloride was used in the first formulation of paracetamol IV. Intravenous paracetamol had been introduced under the brand name Pro-dafalgan in 1985. The propacetamol is hydrolyzed fast with 1:1 ratios in the production of N, N-diethyl glycine as well as paracetamol. Every 2 g of propacetamol generates about 1 gram of paracetamol. The pro-*dafalgan* vials

consist of a transparent crystallized propacetamol dust that will have to be replenished with a solution like water, glucose, sodium citrate as well as water [7]. Propacetamol is soluble in solution and must be infused immediately after reconstitution to prevent oxidation. It was discovered to be an effective antipyretic and analgesic, as well as it was discovered to be an effective antipyretic and analgesic, capable of delivering a quicker reaction than oral and rectal formulations. antipyretic and analgesic, providing a quicker reaction than oral and rectal formulations.

Pharamco-kinetics of Paracetamol

Strong rates of overdose are possibly due to easy availability with which paracetamol is to be accessed over the counter. Paracetamol can metabolize rapidly in GI tract, then primarily via liver in both toxic as well as non-toxic compounds, when administered orally. The amount of its absorption is calculated by calculating the quantity with which the GI tract empties since the absorption from a gastric mucosa is marginal, although it is rapid from small intestine. Though it is considered that the consumption of food will tend to delay the process of gastric emptying, the overall quantity of paracetamol consumed over a period is unaffected. In stable adults, the amount of delivery while in general circulation is about.

Seminal and emerging research offers significant proof that the paracetamol is safe when particularly delivered at the doses greater than that of therapeutic dose (1 g) [8]. Dosages/doses of up to 2 gram acutely and 2 gram 4 doses regularly for several days have been administered for comparative studies on heathy and clinical populations. In humans, the plasma half-life of acute therapeutic (1 gram) and higher dosage of paracetamol (20 milligram up to 1.5 g) varies from 1.5 hours and four hours, with ninety five percent of dosage is excreted fromv urination within 24 hours after absorption as unchanged paracetamolor combined with the sulphuric acid, glucuronic acid, cysteine and mercapturic acid.

Only in population/people having clinical injury of liver is paracetamol plasma half-life extended to and above 4 hours. Usually, the zenith of plasma concentrations in clinical trials is 10–25 g/ml for 1–2 hours following ingestion. If the concentration of plasma is observed to be 200 g/ml observed in 4 hours after ingestion, the possibility of developing hepatotoxicity rises significantly. To put this in perspective, acute pharmaceutical levels of 1 g or marginally higher result in concentration of plasma about 8–25 g/ml. This is approximately 175 g/ml lower than the normal risk of hepatotoxicity and 275 g/ml which is considered to be lower than the defined thresholds for liver harm.

Only in very particular populations has liver injury been identified in relation to therapeutic paracetamol doses—Doses of paracetamol in the liver were detected in just a few populations: persons with alcohol along with the enzyme inducing drugs as well as individuals with infectious disorders, like measles as well as in the infectious mononucleosis. In fact, 1–1.5 g dosing in exercise efficiency tests and 20 mg.kg LBM were utilised with no known side effects in thermophysiological literature; this is not unexpected in view of the prior commentary on plasma ACT levels and hepatic damage. In fact, acute 2g dosages were tolerated without hepatic or some other side-effects.

Despite this, when paracetamol is suggested for utilization in a study setting at acute doses outside of what is usually considered medicinal, it attracts negative reactions (1 g). And if there is evidence that they are completely safe as long as they are not prescribed to the therapeutic groups mentioned above and those doses have also been used on a daily basis. Although no side effects were recorded from acute doses of 2 g and 20 mg.kg, gastrointestinal injury and liver necrosis were not quantified. However, in a series of experiments with liver function (aminotransferase, alanine, aspartate, alkaline phosphatase, aminotransferase, as well as total bilirubin levels) scientists detected zero hepatic adverse impacts on identical doses [9]. Higher dosages beyond clinical dose (6 * 1g/day) for 5-day critically ill patients resulting in six severe liver responses to ibuprofen and paracetamol and 3 to placebo. Overall, adverse effects (gastrointestinal injury, pneumonia, and progressive stroke) were observed similarly in the paracetamol, ibuprofen, and placebo conditions, and thus could not be entirely attributed to either of the treatments.

As a consequence, the management of paracetamol cannot be assigned totally. In addition, it should be highlighted that this result originates from a pathophysiologic population (i.e., severe ischemic attack) that frequently increases biomarkers linked with the identification of "adverse outcomes" connected to liver. For instance, an increase in straight bilirubin is associated to the intensity of a strokes. Indeed, paracetamol was not detected in individuals with mild, moderate or severe chronic liver conditions to induce liver damage. Instead, the half-life of paracetamol is discovered. If not taken into consideration, they can lead in aggregated plasma levels of paracetamol that is typically considered "healthy," causing an unintended overdose and therefore increased liver damage.

The normal clinical dosage of paracetamol (1gram single dose up to 4 gram daily per 4–6 h) have not yet been confirmed for causing liver harm based on the evidence provided here. Extreme doses of up to 1.5 g and dosages of up to 6 mg are permitted. Acute levels of up to 1.5 g, as well as regular doses of up to 6 g, have been found to be stable in clinical and active athlete communities. In clinical and stable athletic communities, doses of up to 6 g/day have been shown to be effective. For such an outstanding safety record, it is clear that these doses/ dosages cannot be deemed a major risk in clinical trials.. However, multiple control/safety initiatives have implemented or may be proposed to offer further reassurance to study participants about these, although minor, dangers. This may include: (1) the use of the substance use disease identification questionnaire; (2)

the use of a breathalyzer (prior to paracetamol ingestion); (3) successful completing a paracetamol risk management questionnaire Following these procedures, whether the study or subject is uncertain about their suitability, medical approval may be received. These guidelines can help to minimize the already low risk of paracetamol-based side effects in otherwise healthy people. And their inclusion into applicable paracetamol-centric study designs should mitigate any legal and/or participant safety issues. These steps have also been used elsewhere.

Effects of Paracetamol

Role of Paracetamol in causing respiratory disease: Aspirin was banned for children under the age of 12, after it was observed to induce the uncommon yet dangerous complication of Reye's syndrome. Concerns about paracetamol's link with asthma was expressed whenever aspirin consumption was raised as an antipyretic decrease in developing nations and use of paracetamol Observational and interdisciplinary research has established a link between the use of paracetamol and the diagnosis or aggravation of asthma. Almost all these data are nevertheless confused by blood-pression indications: recurrent symptoms of respiratory infections and feverish symptoms are more common in asthmatic patients, leading to adolescent asthma [10]. When corrected for chronic respiratory tract infection, an improvement in the risk/odds of contracting asthma with increasing paracetamol use appears nonsignificant in some studies. Meta-analyses of these observational trials usually display very minute impact and are afflicted by substantial heterogeneity.

Role of paracetamol in causing Gastrointestinal (GI) effects: Overdose of paracetamol has been shown to have an acute effect on liver. However, the impact caused by the paracetamol's therapeutic dose on liver and GI is not yet clear as the focus is towards the chronic hepatotoxicity and blood loss via GI.

Paracetamol's connection with Gastrointestinal (GI) bleeding: In patients who are vulnerable to bleeding in GI, the paracetamol has been long considered a "natural" analgesic substitute to NSAIDs. Indeed, due to ethical problems linked with withholding analgesia, it is widely used as a comparator in tests of carrying out for testing NSAIDS' analgesic effects. There are studies that supports the paracetamol's efficacy. Scientists discovered that paracetamol can cause nausea and dyspepsia, but not GI bleeding, as they analysed bad incidents reported in the Spanish drug surveillance system.

Role of paracetamol in causing cardiovascular disease: Studies on the effects of paracetamol upon on incidence of cardiovascular disease is comparably infrequent comparing to NSAIDs. Due to the recognised link between NSAIDs as well as hypertension, and the associated paracetamol mechanism. A trial was conducted which reported a 4 mm Hg blood pressure (BP) rise by the placebo-controlled crossing assessment of 20 hypertension individuals when paracetamol was provided. As it is formally registered that a rise in the thesystolic blood pressure of about 2 mmHg is connected to an elevation in risk of ischo-emic heart disease of 7% as well as an elevation in the risk for stroke of ten percent, this apparently little rise in BP might have major implications.

Role of paracetamol in causing hepatotoxicity: Some of the case reports and limited studies have emerged in recent decades suggesting a linkage between liver damage and the paracetamol's therapeutic dose. For several years, surgical paracetamol use (less than equal to 4 g d-1) has been related to subclinical changes in liver damage markers[11]. However, intermittent changes in *aminotransferase* (ALT) can be caused by a number of causes, including vitamin consumption, exercise, diabetes, drugs (like heparins, statins and aspirin) and congestive heart disease.

It's not certain if such an enzyme increase can cause clinically meaningful liver damage. Scientists noticed that 50% of the paracetamol.

Neurodevelopmental consequences of in taking paracetamol: The relation between fetalexposure of paracetamol and the risk of long term neurological disorders has been the subject of many controversies related topharmaco-epidemiological studies. When compared with controls, Scientists found that maternal paracetamol usage for more than 28 days during pregnancy was associated with issues with communication, externalizing and internalizing behavior, and higher activity levels.

Paracetamol and its association with asthma: The methods through which paracetamol may lead to asthma development have previously been described. It is unknown how access to paracetamol in pregnancy may induce asthma, if the amount of glutathione in the embryo is low enough to influence lung development. Any proof for mother paracetamol usage of offspring originates from animal experiments in which adult mices subjected with paracetamol in gestation were allergic to airways. Enhanced airway infiltration by leucocytes (especially *eosinophils*) has been observed, indicating greater asthma vulnerability even though this conclusion has yet to be verified.

Toxicity to the endocrine and reproductive systems

Cryptorchidism is currently becoming more common, which is specifically worrying due to its link to early adulthood diseases like testicular germ cell cancer and low sperm count. When these conditions are mixed, they form a testicular dysgenesis syndrome, a disease triggered by androgen disturbance during the fetal programming.Prenatally exposed rats to paracetamol had lower testicular PG and testosterone production, as well as a shorter ano–genital gap (a marker for androgen action). Prenatal paracetamol intake is likely to suppress core steroidogenic enzymes (CYP11A1, CYP17A1), which have been linked to lower fetal plasma testosterone and seminal vesicle weight. Notably, one day of exposure had little impact. Another recent research related

paracetamol to decreased germ cell production in human fetal testes and ovary xenografts. This effect was related to PGE2mediated alterations in epigenetic regulatory genes, meaning that paracetamol's effect on the fetus may affect the genetics of future generations.

CONCLUSION

Intravenous paracetamol/acetaminophen (USAN) is an analgesic and antipyretic agent that is used as a 1st therapy for pain and fever in adults and children around the world. For over a century, paracetamol has been commonly used as an analgesic and antipyretic agent. Its effectiveness and tolerability are well known, and it has a favourably safety profile in comparison to other analgesics.

Indeed, paracetamol is the most widely used opioid in children for the relief of mild to severe pain. Furthermore, paracetamol is the only non-opioid analgesic that is used in nasal, rectal, or intravenous forms. Including the NSAID ketorolac, which bears detailed alerts for treatment-related adverse effects such as those mentioned above, and propacetamol, an intravenous prodrug version of paracetamol that involves metabolic activation in vivo. The data is more compelling in two areas: hypertension and GI bleeding.

The 4 mmHg rise in blood pressure at population level is clinically substantial, and the outcomes of current RCTs may clarify the veracity of this prognosis. This is particularly critical in people with angina or hypertension. The relatively substantial evidence of GI bleeding related with the use of paracetamol and its additive impact may be not so well established but similarly relevant in conjunction with NSAIDs. When considering the use of paracetamol inside the chronic setting, these adverse effects should be considered and addressed with patient according to current data.

Although the chronic effects are being observed but the occurrence of these adverse effects are quite uncommon. Therefore, it leaves the paracetamol to be the least-worst option to be used as analgesic and antipyretic.

REFERENCES

1. Farré M, Abanades S, Álvarez Y, et al. Paracetamol. Dolar 2004.
2. Przybyła GW, Szychowski KA, Gmiński J. Paracetamol – An old drug with new mechanisms of action. Clin Exp Pharmacol P 2021;48(1):3-19.
3. Tittarelli R, Pellegrini M, Scarpellini MG, et al. Hepatotoxicity of paracetamol and related fatalities. Eur Rev Med Pharmacol Sci 2017; 21(1): 95-101.
4. Ellis F. Paracetamol - A curriculum resource. R Soc Chem 2002.
5. Dear JW, Bateman DN. Paracetamol poisoning. Medicine (United Kingdom) 2020.
6. Belugina RB, Monakhova YB, Rubtsova E, et al. Distinguishing paracetamol formulations: Comparison of potentiometric 'Electronic Tongue' with established analytical techniques. J Pharm Biomed Anal 2020;188:113457.
7. R, SS. UV-Visible spectrophotometric method of paracetamol tablet formulation. Int J Trend Sci Res Dev 2018;2(5):1749-1753.
8. Lawal MV, Odeniyi MA, Itiola OA. Effect of thermal and chemical modifications on the mechanical and release properties of paracetamol tablet formulations containing corn, cassava and sweet potato starches as filler-binders. Asian Pac J Trop Biomed 2015;5(7):585-590.
9. Reed K, Collaku A, Moreira S. Efficacy and safety of twice daily sustained-release paracetamol formulation for osteoarthritis pain of the knee or hip: A randomized, double-blind, placebo-controlled, twelve-week study. Curr Med Res Opin 2018;34(4):689-699.
10. Ghosh S, Patel J, Patel H, et al. A novel paracetamol 1,000mg sustained release formulation vs conventional paracetamol 500mg formulation in patients with fever and pain: A randomized noninferiority trial. Pain Med (United States) 2013;14(3):436-41.
11. Acheampong A, Gyasi WO, Darko G, et al. Validated RP-HPLC method for simultaneous determination and quantification of chlorpheniramine maleate, paracetamol and caffeine in tablet formulation. Springerplus 2016.